Ocuphire Pharma Inc/ US67577R1023 /
24/05/2024 20:47:56 | Chg. +0.04 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.75USD | +2.34% | 700 Turnover: 1,204 |
-Bid Size: - | -Ask Size: - | 1.75 | 1.71 |
GlobeNewswire
10/05
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
06/05
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire
11/04
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire
01/04
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire
08/03
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
GlobeNewswire
05/02
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire
04/01
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire
30/11/2023
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire
27/11/2023
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
27/11/2023
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
GlobeNewswire
13/11/2023
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
GlobeNewswire
02/11/2023
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Re...
GlobeNewswire
01/11/2023
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01/11/2023
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Offi...
GlobeNewswire
06/10/2023
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
GlobeNewswire
27/09/2023
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.7...
GlobeNewswire
11/09/2023
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
GlobeNewswire
07/09/2023
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September